Orthopaedic gene therapy using recombinant adeno-associated virus vectors
- PMID: 21354554
- DOI: 10.1016/j.archoralbio.2010.12.010
Orthopaedic gene therapy using recombinant adeno-associated virus vectors
Abstract
Use of recombinant adeno-associated virus (rAAV) vectors is increasingly gaining popularity in gene therapy because of their desirable properties, including lack of pathogenicity, efficient transduction of dividing and non-dividing cells, and sustained maintenance of the viral genome. It is these features of rAAV vectors that made them the focus for gene-based therapy of skeletal tissue regeneration. This review outlines the biological characteristics of adeno-associated virus (AAV), states the biological processing as well as current advances of rAAV vectors, and describes the recent achievements of their applications in orthopaedic and craniofacial surgery.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
The use of recombinant adeno-associated virus for skeletal gene therapy.Orthod Craniofac Res. 2007 Feb;10(1):1-14. doi: 10.1111/j.1601-6343.2007.00381.x. Orthod Craniofac Res. 2007. PMID: 17284242 Review.
-
Recombinant adeno-associated virus derived vectors (rAAV2) efficiently transduce ovarian and hepatocellular carcinoma cells--implications for cancer gene therapy.Acta Pol Pharm. 2009 Jan-Feb;66(1):93-9. Acta Pol Pharm. 2009. PMID: 19226976
-
Receptor targeting of adeno-associated virus vectors.Gene Ther. 2003 Jul;10(14):1142-51. doi: 10.1038/sj.gt.3301976. Gene Ther. 2003. PMID: 12833123 Review.
-
Recombinant adeno-associated virus (rAAV) vectors for somatic gene therapy: recent advances and potential clinical applications.Cytokines Mol Ther. 1996 Jun;2(2):69-79. Cytokines Mol Ther. 1996. PMID: 9384691 Review.
-
Recombinant adeno-associated virus type 2 mediates highly efficient gene transfer in regenerating rat skeletal muscle.Gene Ther. 2002 Aug;9(15):1037-43. doi: 10.1038/sj.gt.3301773. Gene Ther. 2002. PMID: 12101435
Cited by
-
Bone repair cells for craniofacial regeneration.Adv Drug Deliv Rev. 2012 Sep;64(12):1310-9. doi: 10.1016/j.addr.2012.03.005. Epub 2012 Mar 10. Adv Drug Deliv Rev. 2012. PMID: 22433781 Free PMC article. Review.
-
Limited potential of AAV-mediated gene therapy in transducing human mesenchymal stem cells for bone repair applications.Gene Ther. 2021 Dec;28(12):729-739. doi: 10.1038/s41434-020-0182-4. Epub 2020 Aug 17. Gene Ther. 2021. PMID: 32807899
-
Gene Delivery Approaches for Mesenchymal Stem Cell Therapy: Strategies to Increase Efficiency and Specificity.Stem Cell Rev Rep. 2017 Dec;13(6):725-740. doi: 10.1007/s12015-017-9760-2. Stem Cell Rev Rep. 2017. PMID: 28815481 Review.
-
Biomechanical characteristics of frozen bone allografts after gene therapy-induced revascularization.Acad Biol. 2025;3(2):10.20935/acadbiol7766. doi: 10.20935/acadbiol7766. Epub 2025 Jun 26. Acad Biol. 2025. PMID: 40837124 Free PMC article.
-
Intra-luminal gene therapy in the porcine artery using a recombinant adeno-associated virus 9.Gene. 2017 Jun 30;618:24-27. doi: 10.1016/j.gene.2017.03.019. Epub 2017 Mar 18. Gene. 2017. PMID: 28322993 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical